Experience

住友ファーマ

• Japan
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Executive Director of Global Business Development

  • Mar 2020 - Present

  Cambridge, Massachusetts, United States Working with DSP, Sunovion and Sumitovant



Regenerate Therapeutics Inc

• Founder and CEO

  • Jan 2019 - Jan 2023

  Boston/Tokyo Regenerate Therapeutics is a private, discovery stage pharmaceutical company focused on developing 1st in class drugs for the treatment of neurotrophic ocular surface diseases (front of the eye), diabetic retinopathy and glaucoma (back of the eye)



住友ファーマ

• Japan
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Head of US and EU and Director of External Innovation Development (EXID)

  • Jul 2015 - Apr 2016

  Kendall Square Cambridge MA I lead US and EU licensing, options, collaborations and seed capital of programs between lead optimization (LO) and Ph IIa (pre-PoC) for DSP group. I report directly to the global head of EXID who is based In Tokyo, however, I will work closely with our US subsidiary Sunovion Pharmaceuticals and will be based at the Cambridge Innovation Center (CIC) in Kendall Sq. We are interested in, but not limited to: Orphan neurology, lysosomal storage diseases, muscle wasting diseases (E.g. cachexia… Show more I lead US and EU licensing, options, collaborations and seed capital of programs between lead optimization (LO) and Ph IIa (pre-PoC) for DSP group. I report directly to the global head of EXID who is based In Tokyo, however, I will work closely with our US subsidiary Sunovion Pharmaceuticals and will be based at the Cambridge Innovation Center (CIC) in Kendall Sq. We are interested in, but not limited to: Orphan neurology, lysosomal storage diseases, muscle wasting diseases (E.g. cachexia, sarcopenia, DMD and BMD), orphan immunology, mitochondrial associated diseases and any highly innovative "high science" programs that are 1st in class with early PoP/PoM readouts. We are interested in working with start-ups, VCs, universities and “Angel Investor companies” (pre-Series A)

• Associate Director Global R&D Strategy Office

  • Apr 2012 - Jul 2015

  Chuo-ku, Tokyo Japan I work in the Global R&D Strategy Office for Dainippon Sumitomo Pharma (DSP) which is the parent company of Sunovion pharmaceuticals. The GRDO is charged with portfolio prioritization, global R&D budgets, R&D strategy and is also the personal staff of the CSO for special projects. I will be in this position for the next ~3 years based in Tokyo



Sunovion Pharmaceuticals

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Associate Director New Products Planning

  • Jul 2011 - Apr 2012

  Marlborough, MA

• Sr. Manager New Products Planning

  • Jul 2010 - Jul 2011

  Marlborough, MA I was the NPP (commercial strategy and opportunities) representative for Sunovion and DSP's early and mid-stage clinical assets chosen to be developed globally in neurology and oncology. I also lead the creation of Sunovion's oncology strategy, a field which they have no history. I was also the commercial representative on the CNS business development evaluation team.



Leerink Swann

• Consultant

  • Apr 2008 - Jul 2010

  Boston, MA Healthcare management consulting focusing on due diligence, opportunity assessments, outsourcing strategy, post-merger integration, pre-launch planning, discovery and clinical development strategies. While at Leerink I worked predominantly for large pharma and biotech but also had projects in medtech and mid-sized biotech.



Abbott

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Scientist, Medicinal Chemistry

  • Sep 2004 - Apr 2008

  Worcester, MA Preclinical drug discovery in immunology (E.g. RA, Crohn's, MS, OA) I was a team member that started the JAK1 program discovering Upadapcitinib. My coworker and I came up with the tricyclic structure core of Upadacitinib and I am named as an inventor on all the composition of matter patents.



Los Alamos National Laboratory

• United States
• Research Services
• 700 & Above Employee

• Research Associate

  • Jan 1998 - Jul 1999

  Los Alamos, NM Catalysis in supercritical fluids (super critical CO2 and super critical Dimethyl Ether) focused on palladium-catalyzed carbon-carbon bond formations Zeolite encased catalysis for the reduction of NOx